Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment

Hu, Jian; Ye, Dong; Ding, Li; Yang, Dong; Wu, Zhihua; Wang, Wenping; Shen, Ming; Duan, Yourong

doi:10.1038/s41392-019-0062-9

Cited by 106 publications

(77 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression was decreased in etoposide-resistant melanoma cells and was negatively associated with cell resistance to etoposide-induced cell death. However, knockout of GSDME protected mice from various organ toxicities and body weight loss induced by chemotherapy drugs [66][67][68]. In the current study, DHP1808 induced less pyroptotic cell death than that of the combined Hsp90 and PI3K inhibitors in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 45%

Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways

Zhao

Zhu

Xie

et al. 2020

IJMS

View full text Add to dashboard Cite

Melanoma is the deadliest form of skin cancer, and its incidence has continuously increased over the past 20 years. Therefore, the discovery of a novel targeted therapeutic strategy for melanoma is urgently needed. In our study, MTT-based cell proliferation assay, cell cycle, and apoptosis assays through flow cytometry, protein immunoblotting, protein immunoprecipitation, designing of melanoma xenograft models, and immunohistochemical/immunofluorescent assays were carried out to determine the detailed molecular mechanisms of a novel HSP90-PI3K dual inhibitor. Our compound, named DHP1808, was found to suppress A375 cell proliferation through apoptosis induction by activating the Fas/FasL signaling pathway; it also induced cell-cycle arrest and inhibited the cell migration and invasion of A375 cells by interfering with Hsp90-EGFR interactions and downstream signaling pathways. Our results indicate that DHP1808 could be a promising lead compound for the Hsp90/PI3K dual inhibitor.

show abstract

Section: Discussionmentioning

confidence: 45%

Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways

Zhao

Zhu

Xie

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Thus, the pyroptotic death will be a new target in cancer therapy. As2O3-NPs HCC Caspase3/GSDME [81] Natural products Galangin Glioblastoma LC3B/caspase3/GSDME [55] Anthocyanin OSCC NLRP3/caspase1/GSDMD [82] Dioscin Osteosarcoma Caspase3/GSDME [83] Berberine HCC Caspase1 [84] Huaier NSCLC NLRP3/caspase1 [85] ESCC: esophageal squamous cell carcinoma. OSCC: oral squamous cell carcinoma.…”

Section: Inducing Cancer Cell Pyroptosis For Cancer Therapymentioning

confidence: 99%

“…Wang et al showed that metformin, a widely used anti-diabetic drug, is able to activate the GSDMD-mediated pyroptosis of ESCC by targeting the miR-497/Proline-, glutamic acidand leucine-rich protein-1 (PELP1) pathway to treat ESCC [80]. Many studies have aimed to determine how to maintain therapeutic Arsenic trioxide (As2O3) concentrations in target solid tumor tissues for long period of time via activation of pyroptosis with few side effects [81,86,87]. Local drug delivery systems can extend the retention time of drugs' administration at the dosing site, resulting in more continuous efficacy and reduced side effects of normal tissues and organs [88,89].…”

Section: Non-chemotherapy Drug-induced Pyroptosis Exerts Anticancer Ementioning

confidence: 99%

See 1 more Smart Citation

Mechanisms and Therapeutic Regulation of Pyroptosis in Inflammatory Diseases and Cancer

Zheng

2020

IJMS

146

111

View full text Add to dashboard Cite

Programmed Cell Death (PCD) is considered to be a pathological form of cell death when mediated by an intracellular program and it balances cell death with survival of normal cells. Pyroptosis, a type of PCD, is induced by the inflammatory caspase cleavage of gasdermin D (GSDMD) and apoptotic caspase cleavage of gasdermin E (GSDME). This review aims to summarize the latest molecular mechanisms about pyroptosis mediated by pore-forming GSDMD and GSDME proteins that permeabilize plasma and mitochondrial membrane activating pyroptosis and apoptosis. We also discuss the potentiality of pyroptosis as a therapeutic target in human diseases. Blockade of pyroptosis by compounds can treat inflammatory disease and pyroptosis activation contributes to cancer therapy.

show abstract

“…This method is most notably used in the fight against cancer, where nanoparticles are an effective tool in localized chemotherapy. By delivering the therapeutic preparation locally, it is retained longer in the affected organ, which reduces the undesirable effect on the rest of the body [40][41][42]. Hu et al confirmed the effectiveness of arsenic trioxide nanoparticles in the fight against malignant liver cancer.…”

Section: Drug Carriersmentioning

confidence: 99%

Analysis of the Exposure of Organisms to the Action of Nanomaterials

et al. 2020

View full text Add to dashboard Cite

The rapid development of the production of materials containing metal nanoparticles and metal oxides is a potential risk to the environment. The degree of exposure of organisms to nanoparticles increases from year to year, and its effects are not fully known. This is due to the fact that the range of nanoparticle interactions on cells, tissues and the environment requires careful analysis. It is necessary to develop methods for testing the properties of nanomaterials and the mechanisms of their impact on individual cells as well as on entire organisms. The particular need to raise public awareness of the main sources of exposure to nanoparticles should also be highlighted. This paper presents the main sources and possible routes of exposure to metal nanoparticles and metal oxides. Key elements of research on the impact of nanoparticles on organisms, that is, in vitro tests, in vivo tests and methods of detection of nanoparticles in organisms, are presented.

show abstract

Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment

Cited by 106 publications

References 39 publications

Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways

Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways

Mechanisms and Therapeutic Regulation of Pyroptosis in Inflammatory Diseases and Cancer

Analysis of the Exposure of Organisms to the Action of Nanomaterials

Contact Info

Product

Resources

About